| 15.04.2025 17:00 | MXCT | Holding(s) in Company | RNS |
| 15.04.2025 14:59 | MXCT | MaxCyte intends to delist from London's AIM to enhance liquidity | Alliance |
| 15.04.2025 07:00 | MXCT | Proposed cancellation of trading on AIM | RNS |
| 14.04.2025 09:17 | MXCT | Holding(s) in Company | RNS |
| 10.04.2025 07:00 | MXCT | MaxCyte to Report Q1 2025 Results on May 7, 2025 | RNS |
| 08.04.2025 15:35 | MXCT | Holding(s) in Company | RNS |
| 01.04.2025 17:57 | MXCT | Total Voting Rights | RNS |
| 26.03.2025 10:14 | MXCT | Correction: Vesting of RSUs and PDMR Dealing | RNS |
| 26.03.2025 07:00 | MXCT | Vesting of RSUs and PDMR Dealing | RNS |
| 25.03.2025 10:30 | MXCT | Holding(s) in Company | RNS |
| 25.03.2025 10:28 | MXCT | Holding(s) in Company | RNS |
| 25.03.2025 10:26 | MXCT | Holding(s) in Company | RNS |
| 25.03.2025 10:22 | MXCT | Holding(s) in Company | RNS |
| 19.03.2025 14:07 | MXCT | Holding(s) in Company | RNS |
| 12.03.2025 07:23 | MXCT | MaxCyte reports wider loss, forecasts revenue growth in 2025 | Alliance |
| 12.03.2025 07:01 | MXCT | Filing of Form 10-K for FY ended December 31, 2024 | RNS |
| 12.03.2025 07:00 | MXCT | Q4 & FY 2024 Financial Results | RNS |
| 04.03.2025 15:38 | MXCT | Total Voting Rights | RNS |
| 04.03.2025 15:12 | SYNT, SUPR, TCAP | UK earnings, trading statements calendar - next 7 days | Alliance |
| 19.02.2025 15:23 | MXCT | Holding(s) in Company | RNS |
| 14.02.2025 17:05 | MXCT | Holding(s) in Company | RNS |
| 13.02.2025 16:12 | MXCT | Holding(s) in Company | RNS |
| 13.02.2025 14:52 | MXCT | Holding(s) in Company | RNS |
| 12.02.2025 09:30 | MXCT | MaxCyte partners with TG Therapeutics on autoimmune cell therapy | Alliance |
| 12.02.2025 07:00 | MXCT | Strategic Platform License with TG Therapeutics | RNS |
| 07.02.2025 07:00 | MXCT | Notice of Results | RNS |
| 04.02.2025 07:00 | MXCT | Total Voting Rights | RNS |
| 31.01.2025 15:18 | MXCT | Exercise of options and PDMR dealing | RNS |
| 30.01.2025 13:55 | MXCT | MaxCyte buys gene therapy analytics firm SeQure Dx | Alliance |
| 30.01.2025 07:00 | MXCT | MaxCyte® Acquires SeQure Dx | RNS |
| 29.01.2025 15:05 | MXCT | Holding(s) in Company | RNS |
| 22.01.2025 14:25 | MXCT | Holding(s) in Company | RNS |
| 21.01.2025 09:13 | MXCT | Holding(s) in Company | RNS |
| 17.01.2025 13:15 | MXCT | Holding(s) in Company | RNS |
| 15.01.2025 16:00 | MXCT | Holding(s) in Company | RNS |
| 13.01.2025 10:43 | MXCT | MaxCyte raises 2024 revenue guide again, ahead of final report | Alliance |
| 13.01.2025 08:05 | MXCT | Preliminary Fourth Quarter and Full Year Results | RNS |
| 02.01.2025 17:53 | MXCT | Total Voting Rights | RNS |
| 31.12.2024 07:00 | MXCT | Exercise of options and PDMR dealing | RNS |
| 23.12.2024 07:00 | MXCT | MaxCyte Announces Retirement of Board Member | RNS |
| 19.12.2024 16:26 | MXCT | Holding(s) in Company | RNS |
| 18.12.2024 15:31 | MXCT | Holding(s) in Company | RNS |
| 09.12.2024 12:29 | MXCT | MaxCyte ups core revenue guidance for 2024 as eyes 2025 cost savings | Alliance |
| 02.12.2024 17:09 | MXCT | Total Voting Rights and Block Listing Return | RNS |
| 28.11.2024 15:05 | MXCT | Holding(s) in Company | RNS |
| 28.11.2024 15:05 | MXCT | Holding(s) in Company | RNS |
| 08.11.2024 14:41 | MXCT | MaxCyte third-quarter profit falls amid surging costs | Alliance |
| 07.11.2024 07:00 | MXCT | Filing of 10Q form | RNS |
| 07.11.2024 07:00 | MXCT | Third Quarter 2024 Financial Results | RNS |
| 06.11.2024 13:43 | MXCT | Exercise of options and PDMR dealing | RNS |
| 04.11.2024 13:23 | MXCT | Total Voting Rights | RNS |
| 31.10.2024 12:05 | MXCT | Upcoming Investor Conferences | Reach |
| 31.10.2024 07:00 | MXCT | Exercise of options and PDMR dealing | RNS |
| 30.10.2024 15:08 | WISE, TLY, PSN | UK earnings, trading statements calendar - next 7 days | Alliance |
| 18.10.2024 09:24 | MXCT | Grant of Options and Restricted Stock Units | RNS |
| 15.10.2024 13:05 | MXCT | MaxCyte Appoints Cynthia Collins to Board | RNS |
| 11.10.2024 13:00 | MXCT | Notice of Results | RNS |
| 10.10.2024 13:05 | MXCT | MaxCyte Appoints Ali Soleymannezhad as CCO | RNS |
| 03.10.2024 09:41 | MXCT | Exercise of options and PDMR dealing | RNS |
| 01.10.2024 09:47 | MXCT | Exercise of options and PDMR dealing | RNS |
| 01.10.2024 07:00 | MXCT | Total Voting Rights | RNS |
| 27.09.2024 16:15 | MXCT | Holding(s) in Company | RNS |
| 27.09.2024 15:29 | MXCT | Holding(s) in Company | RNS |
| 20.09.2024 17:02 | MXCT | Holding(s) in Company | RNS |
| 16.09.2024 10:33 | MXCT | MaxCyte touts strategic platform license deal with Kamau Therapeutics | Alliance |
| 16.09.2024 07:00 | MXCT | TR-1: Notification of major holdings | RNS |
| 16.09.2024 07:00 | MXCT | Signing of Strategic Platform License | RNS |
| 06.09.2024 17:07 | MXCT | Exercise of options and PDMR dealing | RNS |
| 06.09.2024 11:33 | MXCT | Bioprocessing Conference Participation | Reach |
| 03.09.2024 15:38 | MXCT | Total Voting Rights | RNS |
| 29.08.2024 10:06 | MXCT | Exercise of options and PDMR dealing | RNS |
| 07.08.2024 14:10 | MXCT | MaxCyte reaffirms guidance as revenue jumps 24% in first half | Alliance |
| 07.08.2024 07:05 | MXCT | Filing of Form 10-Q | RNS |
| 07.08.2024 07:00 | MXCT | Second Quarter and Half-Year Results | RNS |
| 01.08.2024 16:31 | MXCT | Total Voting Rights | RNS |
